Search Within

Gabriella D'Andrea-Carlino

  1. "Population Sciences Research Program"
Formats
  1. Meeting Abstract (26)
  2. Journal Article (22)
Groups
  1. Breast Medicine Service (48)
  2. Department of Medicine (48)
  3. Population Sciences Research Program (48)
  4. Solid Tumor Oncology Division (48)
  5. Survivorship Research (48)
  6. Epidemiology and Biostatistics (40)

More Groups

People
  1. Clifford Hudis (41)
  2. Diana Lake (30)
  3. Larry Norton (30)
  4. Monica Fornier (30)
  5. Chau Dang (27)
  6. Andrew Seidman (22)

More People

Years
  1. 2023 (1)
  2. 2021 (2)
  3. 2020 (1)
  4. 2018 (1)
  5. 2016 (1)
  6. 2015 (3)

More Years

Publications
  1. Journal of Clinical Oncology (16)
  2. Breast Cancer Research and Treatment (8)
  3. Clinical Cancer Research (7)
  4. Cancer Research (6)
  5. Clinical Breast Cancer (4)
  6. Journal of the American Geriatrics Society (3)

More Publications

Publishers
  1. American Society of Clinical Oncology (16)
  2. American Association for Cancer Research (13)
  3. Springer (9)
  4. Elsevier Inc. (5)
  5. Wiley Blackwell (3)
  6. Biomed Central Ltd (1)

More Publishers

Results (48)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Timing of exercise therapy when initiating adjuvant chemotherapy for breast cancer: A randomized trial
    Journal Article

    Scott, J. M.; Lee, J.; Herndon, J. E.; Michalski, M. G.; Lee, C. P.; O'Brien, K. A.; Sasso, J. P.; Yu, A. F.; Rowed, K. A.; Bromberg, J. F.; more...
    European Heart Journal (2023)

    Fulltext@MSK | Save
  • Toxicity of an Fc engineered anti-CD40 antibody is abrogated by intratumoral injection and results in durable anti-tumor immunity in patients
    Meeting Abstract

    Knorr, D.; Ravetch, J.; D'Andrea, G.; Vahdat, L.; Klebanoff, C.; Robson, M.
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Phase Ib/II study of capecitabine 7/7 schedule with neratinib in patients with HER2-positive metastatic breast cancer (MBC)
    Meeting Abstract

    Wang, R.; Singh, J. C.; Wong, S. T. L.; Lake, D.; Iyengar, N. M.; D'Andrea, G.; Brockway-Marchello, J. P.; Kaba, A.; Traina, T. A.; Robson, M. E.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Phase II trial of bicalutamide in combination with palbociclib for the treatment of androgen receptor (+) metastatic breast cancer
    Meeting Abstract

    Gucalp, A.; Boyle, L. A.; Alano, T.; Arumov, A.; Gounder, M. M.; Patil, S.; Feigin, K.; Edelweiss, M.; D'Andrea, G.; Bromberg, J.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Co-targeting ER and FGFR in patients with ER+/HER2- FGFR amplified (amp) metastatic breast cancer (MBC)
    Meeting Abstract

    Jhaveri, K.; Syed, U.; Wong, S.; D'Andrea, G.; Lake, D.; Goldfarb, S.; Gajria, D.; Ligresti, L.; Rogado, A.; Reis-Filho, J.; more...
    European Journal of Cancer (2018)

    Fulltext@MSK | Save
  • A pilot study of dose-dense paclitaxel with trastuzumab and lapatinib for node-negative HER2-overexpressed breast cancer
    Journal Article

    Iyengar, N. M.; Fornier, M. N.; Sugarman, S. M.; Theodoulou, M.; Troso-Sandoval, T. A.; D'Andrea, G. M.; Drullinsky, P. R.; Gajria, D.; Goldfarb, S. B.; Comen, E. A.; more...
    Clinical Breast Cancer (2016)

    Fulltext@MSK | Save
  • Phase I study of PI3Kα inhibitor BYL719 + aromatase inhibitor (AI) in patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Moynahan, M. E.; Modi, S.; Hamilton, N.; Caravella, B. A.; Zamora, S.; Dang, C.; Gilewski, T.; Traina, T.; Comen, E.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • Phase I trial: PI3Kα inhibitor BYL719 plus aromatase inhibitor (AI) for patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Moynahan, M. E.; Modi, S.; Caravella, B. A.; Datko, F. M.; Zamora, S.; Comen, E.; Gilewski, T.; Sugarman, S. M.; D'Andrea, G.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer
    Journal Article

    Dang, C.; Iyengar, N.; Datko, F.; D'Andrea, G.; Theodoulou, M.; Dickler, M.; Goldfarb, S.; Lake, D.; Fasano, J.; Fornier, M.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Phase I trial of daily PI3K alpha inhibitor BYL719 plus letrozole (L) or exemestane (E) for patients (pts) with hormone receptor-positive (HR plus ) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Modi, S.; Datko, F. M.; Moynahan, M. E.; Zamora, S.; D'Andrea, G.; Lake, D.; Goldfarb, S. B.; Patil, S.; Singh, S.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save